2025 Provide Updated RAPS RAC-US Dumps as Practice Test and PDF
RAC-US Dumps are Available for Instant Access
The RAC-US certification is a recognized credential that demonstrates that a regulatory affairs professional has the knowledge, skills, and expertise required to navigate the regulatory landscape. Regulatory Affairs Certification (RAC) US certification is offered by the Regulatory Affairs Professionals Society (RAPS), a global organization that represents regulatory professionals worldwide. The RAC-US certification exam is designed to assess the knowledge and skills of regulatory affairs professionals in the United States. RAC-US exam covers various topics such as regulatory strategy, product development, clinical trial design, and post-marketing activities.
RAPS RAC-US (Regulatory Affairs Certification US) exam is a professional certification exam designed for regulatory professionals in the United States. RAC-US exam is created and administered by the Regulatory Affairs Professionals Society (RAPS) to test the knowledge and expertise of regulatory professionals in the US. Passing the RAC-US exam demonstrates a regulatory professional's ability to understand and navigate the complex regulatory environment of the United States.
NEW QUESTION # 55
What are the MOST important elements that global regulatory agencies want to know before approving a new product for sale in their countries?
- A. Safety and effectiveness
- B. Quality and failure risk
- C. Quality and effectiveness
- D. Safety and failure risk
Answer: A
NEW QUESTION # 56
The API used for an approved drug product conforms to international monograph specifications and local pharmacopeia; however, the international monograph specifications of the API will be changing soon. Which is the most appropriate action for the regulatory affairs professional to take FIRST?
- A. Analyze the impact of the international monograph change on the local pharmacopeia.
- B. Prepare the international monograph change submission first and then prepare the local change when required.
- C. Transfer the notice of the upcoming international monograph change to QA for further processing.
- D. Confirm that the international monograph change is not related to local pharmacopeia.
Answer: C
NEW QUESTION # 57
Which of the following criteria is MOST appropriate to define the animal species needed for the pre-clinical toxicity testing of a biotechnology product?
- A. Proposed dose and volume of administration
- B. Proposed product route and frequency of administration
- C. Biological activity with species and/or tissue specificity
- D. Immunochemical and functional tests
Answer: C
NEW QUESTION # 58
A protocol for a pivotal registration trial of a new product is submitted to a major regulatory authority for review and approval. The regulatory authority issues the company a written commitment that if the studies are completed as outlined in the protocol and the results meet the pre-specified criteria for efficacy and safety, the product will be approved.
During the final week of the review of the marketing application, which has fully met all pre- specified criteria, the company receives a letter from the regulatory authority stating that it no longer believes that the product will be approved based on a recent withdrawal of a similar product in another country.
What is the BEST response?
- A. Review the regulatory guidelines to determine how to proceed.
- B. Consult with the legal department to discuss the best course of action.
- C. Notify the regulatory authority regarding Its obligation to honor the commitment to approve the application.
- D. Request a meeting with the regulatory authority to discuss the application.
Answer: D
NEW QUESTION # 59
What is the LAST stage in the development of a quality risk management process for a medical device?
- A. Risk evaluation
- B. Risk acceptance
- C. Risk analysis
- D. Risk reduction
Answer: B
NEW QUESTION # 60
SOPs for preventive and corrective actions MUST include the procedure to eliminate which of the following?
- A. Adverse environmental impacts
- B. Late and/or incorrect deliverables
- C. Causes of non-conformities
- D. Inadequate training
Answer: C
NEW QUESTION # 61
According to ICH, which of the following components of study information is NOT required in a clinical study report?
- A. Randomization scheme and codes
- B. Protocol and protocol amendments
- C. List of lECs or lRBs
- D. Detailed CV of all investigators
Answer: D
NEW QUESTION # 62
Which of the following situations does NOT require rapid communication to regulatory authorities?
- A. A statistically significant increase in the number of deaths in an animal dose finding study
- B. A clinically important increase in the rate of occurrence of an "expected." but serious
ADR - C. A lack of efficacy with a medicinal product used in treating a life-threatening disease
- D. A major safety finding from a newly completed animal carcinogenicity study
Answer: B
NEW QUESTION # 63
As a member of the product launch review committee, a regulatory affairs professional discovers a major issue with the labeling of a product prior to production. In addition to informing the committee, which is the BEST approach to address the issue?
- A. Abort the product launch.
- B. Correct the label text.
- C. Inform the regulatory authorities.
- D. Delay the start of product production.
Answer: C
NEW QUESTION # 64
Company X acquires Company Y.
Both companies produce pharmaceuticals distributed globally. A regulatory authority requires that all labeling for Company Y's products be converted to Company X within three months. The regulatory affairs professional at
Company X concludes that it is not feasible to meet this request within the time frame.
Which is the FIRST step that the regulatory affairs professional at Company X should take to address the situation?
- A. Develop a plan of action with tasks, timelines, and responsibilities and request an extension period from the regulatory authority.
- B. Submit as many labeling conversion applications as possible within the time frame and request an extension for the remaining ones.
- C. Request additional resources from senior management in order to complete the labeling conversion within the time frame given by the regulatory authority.
- D. Convene an urgent meeting with internal stakeholders to inform them of the regulatory authority requirement and assign responsibilities.
Answer: A
NEW QUESTION # 65
A manufacturer is involved in a recall event process for a plasma-derived product. From which stage should the manufacturer be able to trace back the product?
- A. Plasma fractionation
- B. Product distribution
- C. Individual plasma donation
- D. Plasma pooling
Answer: B
NEW QUESTION # 66
At a recent scientific meeting, Company Y had two booths:
* At one booth, Company Y provided brochures on a completed Phase II study.
* In an adjacent booth, Company Y's sales professionals were promoting one of Company
Y's marketed products.
A regulatory affairs-professional at Company X sends a letter to a counterpart at Company
Y requesting that Company Y stop this practice in the future and demanding a formal response to the letter. How should the regulatory affairs professional at Company Y BEST respond?
- A. Inform the local regulatory authority of the letter and discuss how to respond.
- B. Acknowledge receipt of the letter in a written response but do nothing further.
- C. Inform the legal department of the letter and discuss how to respond.
- D. Inform Company X that it has no right to send such a letter and do nothing further.
Answer: C
NEW QUESTION # 67
In order to develop a global drug product, what is the MOST important environmental characteristic to consider in the country of intended use?
- A. Product stability
- B. Product formulation
- C. Product registration
- D. Product requirements
Answer: A
NEW QUESTION # 68
Which of the following BEST describes the content of the "Physical, Chemical, and
Pharmaceutical Properties and Formulation" section of an IB?
- A. A description and flow chart illustrating the synthetic route for the active ingredient and the preparation method of the finished product
- B. A detailed summary of the physical and chemical properties of the drug product with a signed expert statement addressing the suitability and stability of the formulation for its intended use
- C. A brief summary of relevant physical, chemical, and pharmaceutical properties:
instructions for storage and handling of the dosage form: and a description of the formulation - D. A review of available data to support the determination of the chemical structure and physical attributes of the drug substance plus batch analysis and stability data for the finished formulation
Answer: C
NEW QUESTION # 69
A company is developing a new medical device using innovative technology. Which of the following is MOST critical in working with regulatory authorities?
- A. Early collaboration
- B. Frequent communication
- C. Follow-up meeting after submission
- D. Documented agreement
Answer: B
NEW QUESTION # 70
A global company has obtained a patent in a specific country for a newly marketed product.
What would be the BEST advice In order to protect the patent in other countries?
- A. File patents of interest in target countries.
- B. Use the community patent system.
- C. Use the Madrid system.
- D. File design patents in target countries.
Answer: A
NEW QUESTION # 71
An inspection of a manufacturing site determines that a number of manufacturing changes have been implemented without obtaining the necessary regulatory clearance. Which of the following actions should the regulatory affairs professional complete FIRST?
- A. Establish validation procedures.
- B. Stop product manufacturing.
- C. Assess the impact of the changes.
- D. Review the stability data for the changes.
Answer: B
NEW QUESTION # 72
A regulatory authority announces an inspection of a regulatory affairs professional's facility during a holiday season when most of the staff Is not available. What is the MOST practical approach to this dilemma?
- A. Negotiate with colleagues and the authority to find a better time.
- B. Insist that key personnel be available for the inspection.
- C. Inform the authority that the time is not suitable and request a new time
- D. Arrange for an inspection without all intended personnel.
Answer: A
NEW QUESTION # 73
......
Updated RAC-US Dumps Questions For RAPS Exam: https://itexambus.passleadervce.com/RAC-Regulatory-Affairs-Certification/reliable-RAC-US-exam-learning-guide.html